Emerging Therapeutics

Here’s our an overiew of our coverage of promising and sometimes uncertain modalities currently under research — or should be — so we call them emerging therapeutics:

Psychedelics and Entactogen Emerging Therapeutics

• Anesthetic / dissociatives with anti-depressant effect
  • Methoxetamine
• The “Classic” Psychedelics
  • Shrooms and shroom-like molecules
    • Psilocybin
    • Psilocin
    • DMT
    • 5-Meo-DMT
  • LSD and highly-related analogs
• Phenylethylamines
  • Entactogens aka serotonin-releasing drugs
    • MDMA
    • MDA
    • MBDB
  • Psychedelic amphetamines
    • DOI
    • DOC
    • DOB
  • 2Cs – not to be confused with “tusi”
    • 2CB
    • 2CI
    • other 2Cs

Drugs Used Naturalistically and in Approved Pharmaceuticals

• GHB / sodium oxybate – in Xyrem-branded pharmaceutical
• Ketamine
• Cocaine
• Cannabinoids
• Amphetamines
  • Methamphetamine

Drugs (New Psychoactive Substances – NPSs)

These are sometimes known in the underground to be anticipated to reduce harm and with useful potential in drug design and pharmaceuticals research.

Anesthetic / dissociatives with anti-depressant effect

• Methoxetamine

We like to highlight not only the benefits, but the risks of emerging therapeutics. Here’s an outline of topics we’re prioritizing: Unaddressed Risks in Emerging Clinical Use of Psychedelics. We also have this article addressing how to be more aware of harmful ketamine use.